Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction

Heart

Volumn 78, Issue 3, 1997, Pages 278-284

  Hirohata, Satoshi ^a   Kusachi, Shozo ^a   Murakami, Masahiro ^a   Murakami, Takashi ^a   Sano, Issei ^a   Watanabe, Tomoko ^a   Komatsubara, Issei ^a   Kondo, Jun ^a   Tsuji, Takao ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Fibrosis; Left ventriculography; Matrix metalloproteinase 1; Tissue inhibitor of metalloproteinase 1; Ventricular remodelling

Indexed keywords

COLLAGENASE; CREATINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EXTRACELLULAR MATRIX; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; HEART VENTRICULOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; WOUND HEALING;

EID: 0030861387     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.78.3.278     Document Type: Article

References (33)

1. Kostuk WJ, Kazamias TM, Gander MP, Simon AL, Ross J. Left ventricular size after acute myocardial infarction: serial changes and their prognostic significance. Circulation 1973;47:1174-9.
2. White HD, Norris RM, Brown MA, Brandt PWT, Whitelock RML, Wild CJ, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
3. Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis 1987;30:73-110.
4. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72.
5. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
6. Werb Z. The biologic role of metalloproteinases and their inhibitors. In: Kuettner K, Schleyerbach R, Peyron JG, Hascall VC, eds. Articular cartilage and osteoarthritis. New York: Raven Press, 1992:295-305.
7. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77: 863-8.
8. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981;195:159-65.
9. Murphy G, Cawston TE, Reynolds JJ. An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. Biochem J 1981;195:167-70.
10. Murawaki Y, Kawasaki H, Burkhardt H. Serum collagenase activity in chronic liver diseases. Path Res Pract 1994;190:929-33.
11. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
12. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LSC, et al. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975;51(suppl):5-40.
13. Kloorwijk P, Cobbaert C, Fioretti P, Kint PP, Simoons ML. Noninvasive assessment of reperfusion and reocclusion after thrombolysis in acute myocardial infarction. Am J Cardiol 1993;72:75-84G.
14. Arnold AZ, Topol EJ. Assessment of reperfusion after thrombolytic therapy for myocardial infarction. Am Heart J 1992;124:441-7.
15. Zhang J, Fujimoto N, Iwata K, Iwata H, Sakai T, Okada Y, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase-1 (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta 1993;219:1-14.
16. Fujimoto N, Iwata K. Enzyme immunoassay for matrix metalloproteinases and their inhibitors. Connective Tissue 1994;26:237-44 (Japanese with English abstract and tables).
17. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990;127:103-8.
18. Greene DG, Carlisle R, Grant C, Bunnell IL. Estimation of left ventricular volume by one-plane cineangiography. Circulation 1967;35:61-9.
19. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HW. Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation 1986;74:293-305.
20. Rosalki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967;69: 696-705.
21. Norris RM, Whitlock RM, Barratt-Boyes C, Small CW. Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. Circulation 1975;51:614-20.
22. Shell WE, Kjekshus JK, Sohel BE. Qualitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest 1971;50: 2614-25.
23. Horie M, Yasue H, Omote S, Takizawa A, Nagao M, Nishida S, et al. A new approach for the enzymatic estimation of infarct size: serum peak creatine kinase and time to peak creatine kinase activity. Am J Cardiol 1986; 57:76-81.
24. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27: 1281-92.
25. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin-1 and tumor necrosis factor of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta 1990;1052: 366-78.
26. Manicourt D-H, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1 and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenie keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995;38:1031-9.
27. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419-28.
28. Latini R, Bianchi M, Correale E, Dinarello CA, Fantuzzi G, Fresco C, et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994;23:1-6.
29. Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992; 93:651-7.
30. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 1995;27:2177-89.
31. Stricklin GP, Li L, Jancic V, Wenczak BA, Nanney LB. Localization of mRNAs representing collagenase and TIMP in sections of healing human burn wounds. Am J Pathol 1993;143:1657-66.
32. Barrett AJ, Starkey PM. The interaction of α2-macroglobulin with proteinases, Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973;113:709-24.
33. Enghild JJ, Salvesen G, Brew K, Nagase H. Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromyelysin (matrix metalloproteinase 3) with human α2-macroglobulin and chicken ovostatin. J Biol Chem 1989;264:8779-85.